We are live on
!
Find out more
MACM
March Altus Capital Management Portfolio holdings
AUM
$16M
1-Year Est. Return
18.92%
This Fund
S&P 500
This Quarter
Est. Return
-8.76%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$17M
AUM Growth
-$224K
(-1.3%)
Cap. Flow
+$2.44M
Cap. Flow
% of AUM
14.36%
Top 10 Holdings %
Top 10 Hldgs %
86.05%
Holding
28
New
8
Increased
3
Reduced
3
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$4.93M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$2.03M |
| 3 |
Gilead Sciences
GILD
|
+$1.91M |
| 4 |
PETX
Aratana Therapeutics, Inc.
PETX
|
+$1.87M |
| 5 |
MDVN
MEDIVATION, INC.
MDVN
|
+$931K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Universal Health Services
UHS
|
+$2.08M |
| 2 |
United Therapeutics
UTHR
|
+$1.2M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.07M |
| 4 |
THOR
THORATEC CORPORATION
THOR
|
+$1.05M |
| 5 |
CYNO
Cynosure, Inc. Class A
CYNO
|
+$983K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Edwards Lifesciences
EW
$50B
| $4.84M | 28.53% |
+204,414
| New | +$4.93M |
|
|
2
Gilead Sciences
GILD
$163B
| $1.69M | 9.92% |
+17,162
| New | +$1.91M |
|
|
3
Acadia Pharmaceuticals
ACAD
$4.55B
| $1.61M | 9.51% |
+48,825
| New | +$2.03M |
|
4
Eli Lilly
LLY
$1.03T
| $1.41M | 8.3% |
16,844
+1,106
| +7% | +$93.4K |
|
|
PETX
5
DELISTED
Aratana Therapeutics, Inc.
PETX
| $935K | 5.51% |
+110,537
| New | +$1.87M |
|
6
DexCom
DXCM
$28.8B
| $841K | 4.95% |
39,176
-22,840
| -37% | -$510K |
|
|
MDCO
7
DELISTED
Medicines Co
MDCO
| $838K | 4.94% |
+22,077
| New | +$775K |
|
8
Regeneron Pharmaceuticals
REGN
$77.4B
| $817K | 4.81% |
1,756
-538
| -23% | -$289K |
|
|
MNK
9
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $816K | 4.81% |
12,769
+4,592
| +56% | +$455K |
|
10
Incyte
INCY
$24.9B
| $810K | 4.77% |
+7,344
| New | +$823K |
|
|
MDVN
11
DELISTED
MEDIVATION, INC.
MDVN
| $799K | 4.71% |
+18,794
| New | +$931K |
|
12
Neurocrine Biosciences
NBIX
$18.7B
| $692K | 4.08% |
17,386
+8,793
| +102% | +$425K |
|
|
AERI
13
DELISTED
Aerie Pharmaceuticals
AERI
| $549K | 3.23% |
+30,962
| New | +$561K |
|
|
14
United Therapeutics
UTHR
$26.2B
| $328K | 1.93% |
2,500
-7,509
| -75% | -$1.2M |
|
|
AGEN
15
Agenus
AGEN
$329M
| – | – |
-943
| Closed | -$160K |
|
16
Cigna
CI
$76.1B
| – | – |
-4,842
| Closed | -$784K |
|
17
Cencora
COR
$60.7B
| – | – |
-6,707
| Closed | -$713K |
|
|
CPRX
18
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-80,890
| Closed | -$334K |
|
19
Humana
HUM
$44B
| – | – |
-3,862
| Closed | -$739K |
|
20
Ultragenyx Pharmaceutical
RARE
$2.56B
| – | – |
-3,299
| Closed | -$338K |
|
|
21
Universal Health Services
UHS
$9.88B
| – | – |
-14,663
| Closed | -$2.08M |
|
22
Zoetis
ZTS
$31.9B
| – | – |
-14,956
| Closed | -$721K |
|
|
SGEN
23
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-8,768
| Closed | -$424K |
|
|
ALXN
24
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-5,949
| Closed | -$1.07M |
|
|
ZLTQ
25
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| – | – |
-18,165
| Closed | -$535K |
|
Similar funds
IC
PA
GMIM
JHWCP
SMPIAI
NCMG
CAD
GPI
March Altus Capital Management's Q3 2015 Portfolio in Review
As of Q3 2015, March Altus Capital Management held 28 positions worth $17M, down 1.3% from $17.2M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
March Altus Capital Management deployed $2.44M of net new capital in Q3 2015, opening 8 new positions and adding to 3 existing holdings. Its largest new stake was Edwards Lifesciences: 204,414 shares worth $4.84M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier.
On the sell side, the largest reduction was United Therapeutics, an estimated $1.2M trimmed.
- March Altus Capital Management's largest Q3 2015 buy was Edwards Lifesciences: 204,414 shares worth $4.84M.
- March Altus Capital Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q3 2015, an estimated $455K increase.
- March Altus Capital Management's biggest Q3 2015 reduction was United Therapeutics, cutting an estimated $1.2M.
- March Altus Capital Management fully exited Universal Health Services in Q3 2015, selling an estimated $2.08M.
- March Altus Capital Management's ten largest holdings make up 86% of its $17M portfolio in Q3 2015.
- March Altus Capital Management opened 8 new positions and closed 14 in Q3 2015.
- March Altus Capital Management's portfolio value fell 1.3% quarter-over-quarter to $17M.
Based on March Altus Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.